Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3980036 | Cancer Treatment Reviews | 2013 | 6 Pages |
Abstract
Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may be more effective. The present work summarizes and discusses clinical trials that have aimed to test the benefits of administering fulvestrant at a higher dose. The data support the use of a higher, and more possibly, effective dose of the agent.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
L. Estévez, I. Alvarez, I. Tusquets, M.A. Seguí, M. Muñoz, Y. Fernández, A. Lluch,